Organization
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2 abstracts
Abstract
Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,
Abstract
Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial.Org: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China, Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, China,